After Coup, Verastem Navigates Choppy Waters

Two-year-old Verastem, which raised $55 million in an initial public offering in late January, was one of the first biotechnology start-ups in years to take its shares public before its drugs had entered clinical trials, a coup in an era of skeptical investors.
Boston Globe